CLINICURO ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  8.5% 12.5% 8.5% 9.6% 8.2%  
Credit score (0-100)  30 20 29 24 29  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  -0.0 -0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6

Net sales  0 0 0 0 0  
Gross profit  428 268 90.4 268 333  
EBITDA  228 117 -112 -218 -162  
EBIT  228 117 -112 -218 -162  
Pre-tax profit (PTP)  194.8 97.6 -129.7 -245.3 112.3  
Net earnings  150.9 77.1 -193.8 -245.3 112.3  
Pre-tax profit without non-rec. items  215 97.6 -130 -245 112  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  -323 -246 78.6 -167 -573  
Interest-bearing liabilities  482 407 413 762 1,085  
Balance sheet total (assets)  293 257 728 708 638  

Net Debt  435 305 403 762 1,085  
 
See the entire balance sheet

Volume 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  428 268 90.4 268 333  
Gross profit growth  184.0% -37.3% -66.3% 197.0% 23.9%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  293 257 728 708 638  
Balance sheet change%  56.0% -12.1% 182.6% -2.7% -9.8%  
Added value  228.4 117.2 -111.8 -217.6 -162.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 -1.0 -2.0 -3.0  

Profitability 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  53.4% 43.7% -123.7% -81.1% -48.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  34.1% 20.9% -18.2% -27.2% -45.5%  
ROI %  47.2% 26.4% -24.9% -34.7% 16.3%  
ROE %  62.8% 28.0% -115.3% -62.4% 16.7%  

Solidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Equity ratio %  -52.4% -48.9% 10.8% -19.1% -47.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  190.4% 260.6% -360.7% -349.9% -669.6%  
Gearing %  -149.2% -165.3% 525.6% -456.7% -189.4%  
Net interest  0 0 0 0 0  
Financing costs %  4.6% 4.4% 4.4% 4.7% 4.1%  

Liquidity 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Quick Ratio  0.5 0.4 0.2 0.0 0.0  
Current Ratio  0.5 0.5 0.3 0.2 0.3  
Cash and cash equivalent  47.2 101.2 9.6 0.0 0.0  

Capital use efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -323.1 -246.0 -439.7 -685.0 -885.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2019/6
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
Net sales / employee  0 0 0 0 0  
Added value / employee  228 117 -112 -218 -162  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  228 117 -112 -218 -162  
EBIT / employee  228 117 -112 -218 -162  
Net earnings / employee  151 77 -194 -245 112